Point72 Asset Management’s Cytokinetics CYTK Stock Holding History

Point72 Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455K	Sell	6,900 -4,200	-38%	-$267K	﹤0.01%	3158
2025 Q4	$705K	Sell	11,100 -18,900	-63%	-$1.18M	﹤0.01%	3055
2025 Q3	$1.65M	Sell	30,000 -25,000	-45%	-$1.03M	﹤0.01%	1521
2025 Q2	$1.82M	Buy	+55,000	New	+$1.91M	﹤0.01%	1347
2024 Q4	–	Sell	-40,000	Closed	-$2.11M	–	2137
2024 Q3	$2.11M	Buy	40,000 +20,000	+100%	+$1.11M	0.01%	1179
2024 Q2	$1.08M	Buy	+20,000	New	+$1.21M	﹤0.01%	1254
2024 Q1	–	Sell	-220,000	Closed	-$18.4M	–	2270
2023 Q4	$18.4M	Buy	220,000 +180,000	+450%	+$6.52M	0.04%	457
2023 Q3	$1.18M	Buy	+40,000	New	+$1.33M	﹤0.01%	1280

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management's CYTK Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Cytokinetics (CYTK) in Q1 2026: 626,102 shares worth $41.3M. The stake represents 0.05% of the portfolio and ranks #455 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in CYTK as recently as Q3 2025.

Point72 Asset Management first reported a position in CYTK in Q2 2019 and has held it in 24 quarters since. The position peaked at $69.2M in Q1 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Point72 Asset Management held 626,102 shares of Cytokinetics worth $41.3M as of Q1 2026.
Cytokinetics was a new Point72 Asset Management position in Q1 2026.
Cytokinetics made up 0.05% of Point72 Asset Management's portfolio in Q1 2026, its #455 holding.
Point72 Asset Management first reported a position in Cytokinetics in Q2 2019 and has held it in 24 quarters since.
Point72 Asset Management's Cytokinetics position peaked at $69.2M in Q1 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.